MLTH news

Latest 1 stories · newest Jun 22, 2026

MLTH

MapLight Therapeutics releases Phase 2 IRIS trial topline data for ML-004 in autism

MapLight Therapeutics announced topline data from its Phase 2 IRIS trial evaluating ML-004 for autism spectrum disorder treatment. The clinical trial results represent a key milestone in the company's development pipeline for this therapeutic candidate.

Regulatory Jun 22, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MLTH feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MLTH/newsSTART FREE